StockData

CytoMed Therapeutics vs Scienture

GDTC and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GDTC and SCNX compare

CytoMed Therapeutics scores higher on the StockData Score (4 against 3 for Scienture), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGDTCSCNX
Size and price
Market cap–$113M
Share price$0.783$2.76
Change, 1 year−60.1%−82.8%
Change, 5 years–−99.8%
Beta (5Y)−0.421.19
Employees58
StockData Score
Total score4 (better)3
Valuation score01 (better)
Growth score1 (better)0
Performance score11
Health score2 (better)1
Dividend score00
Valuation
P/B–1.8×
Growth
Revenue growth (TTM)367%–
Revenue growth, 5Y average–−52.1%
Profitability
Net margin−1227%–
FCF margin−1336%–
Return on equity−51.3% (better)−53.5%
Return on invested capital–−47.3%
Financial health
Debt / equity0.06–
Interest coverage–−13.1×
Current ratio5.17 (better)3.04
Altman Z-score–0.07
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.10%–
Held by insiders25.9%16.6%
Insider net buying, 12 months$729K–
Short interest, % of float–0.34%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.